グルココルチコイドは乳がんの転移を促進する

Milan M S Obradović^1,2,3, Baptiste Hamelin¹, Nenad Manevski^4,5

¹Department of Biomedicine, Department of Surgery, University Hospital Basel, University of Basel, Basel, Switzerland.

Nature

|March 15, 2019

まとめ

遠隔転移におけるグルココルチコイド受容体の活性化は,癌の異質性と拡散を促す. これは,合併症のある乳がん患者に対してグルココルチコイドを使用する際の注意を促す.

科学分野:

腫瘍学
分子生物学
癌研究

背景:

患者内における腫瘍の異質性と転移は,がん治療における主要な障害である.
転移のメカニズムと腫瘍の異質性を理解することは,個別化されたがん治療に不可欠です.

研究の目的:

患者内における腫瘍の異質性と転移におけるグルココルチコイド受容体の作用を調査する.
乳がん治療の成果を改善するための分子標的を特定する.

主な方法:

患者からの異種移植モデルにおける腫瘍とマッチングした転移の転写プロファイリング.
プロテオミクスとフォスフォプロテオミクス分析
ROR1の消去が転移と生存に与える影響の評価

主要な成果:

遠隔転移ではグルココルチコイド受容体の活性が増加し,がん部位特異的な表型と相関していました.
グルココルチコイド受容体の活性化は,コロニー化,異質性,生存率の低下と関連していた.
キナーゼROR1の発現増加は転移に関連し,生存率の低下と相関していた.

結論:

グルココルチコイド受容体の活性化は,乳がんにおける腫瘍の異質性と転移を促進する.
ROR1を標的とした治療は,転移を減少させ,生存率を向上させるための治療戦略である.
乳がん患者には,転移や生存に対する潜在的な有害作用による合併症がある場合,グルココルチコイドを投与する際には注意が必要です.

さらに関連する動画

05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.8K

07:47

Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis

Published on: June 26, 2016

10.2K

関連する概念動画

02:30

Metastasis

6.6K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

6.6K

02:40

The Eukaryotic Promoter Region

18.7K

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...

18.7K

02:40

The Eukaryotic Promoter Region

3.9K

01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.5K

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

1.5K

01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

476

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

476

00:50

Anaphase Promoting Complex

3.4K

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...